Literature DB >> 19259985

The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts.

Nadiya M Teplyuk1, Larisa M Haupt, Ling Ling, Christian Dombrowski, Foong Kin Mun, Saminathan S Nathan, Jane B Lian, Janet L Stein, Gary S Stein, Simon M Cool, Andre J van Wijnen.   

Abstract

Heparan sulfate proteoglycans cooperate with basic fibroblast growth factor (bFGF/FGF2) signaling to control osteoblast growth and differentiation, as well as metabolic functions of osteoblasts. FGF2 signaling modulates the expression and activity of Runt-related transcription factor 2 (Runx2/Cbfa1), a key regulator of osteoblast proliferation and maturation. Here, we have characterized novel Runx2 target genes in osteoprogenitors under conditions that promote growth arrest while not yet permitting sustained phenotypic maturation. Runx2 enhances expression of genes related to proteoglycan-mediated signaling, including FGF receptors (e.g., FGFR2 and FGFR3) and proteoglycans (e.g., syndecans [Sdc1, Sdc2, Sdc3], glypicans [Gpc1], versican [Vcan]). Runx2 increases expression of the glycosyltransferase Exostosin-1 (Ext1) and heparanase, as well as alters the relative expression of N-linked sulfotransferases (Ndst1 = Ndst2 > Ndst3) and enzymes mediating O-linked sulfation of heparan sulfate (Hs2st > Hs6st) or chondroitin sulfate (Cs4st > Cs6st). Runx2 cooperates with FGF2 to induce expression of Sdc4 and the sulfatase Galns, but Runx2 and FGF2 suppress Gpc6, thus suggesting intricate Runx2 and FGF2 dependent changes in proteoglycan utilization. One functional consequence of Runx2 mediated modulations in proteoglycan-related gene expression is a change in the responsiveness of bone markers to FGF2 stimulation. Runx2 and FGF2 synergistically enhance osteopontin expression (>100 fold), while FGF2 blocks Runx2 induction of alkaline phosphatase. Our data suggest that Runx2 and the FGF/proteoglycan axis may form an extracellular matrix (ECM)-related regulatory feed-back loop that controls osteoblast proliferation and execution of the osteogenic program.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259985      PMCID: PMC2918404          DOI: 10.1002/jcb.22108

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  50 in total

1.  Mitotic partitioning and selective reorganization of tissue-specific transcription factors in progeny cells.

Authors:  Sayyed K Zaidi; Daniel W Young; Shirwin M Pockwinse; Amjad Javed; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

2.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

3.  Transcriptional activation of c-fos and c-jun protooncogenes by serum growth factors in osteoblast-like MC3T3-E1 cells.

Authors:  R Okazaki; K Ikeda; A Sakamoto; T Nakano; K Morimoto; T Kikuchi; K Urakawa; E Ogata; T Matsumoto
Journal:  J Bone Miner Res       Date:  1992-10       Impact factor: 6.741

4.  Nomenclature for Runt-related (RUNX) proteins.

Authors:  Andre J van Wijnen; Gary S Stein; J Peter Gergen; Yoram Groner; Scott W Hiebert; Yoshiaki Ito; Paul Liu; James C Neil; Misao Ohki; Nancy Speck
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

5.  A gene network for navigating the literature.

Authors:  Robert Hoffmann; Alfonso Valencia
Journal:  Nat Genet       Date:  2004-07       Impact factor: 38.330

6.  The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2.

Authors:  Hyun-Jung Kim; Jung-Hwan Kim; Suk-Chul Bae; Je-Yong Choi; Hyun-Jung Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

Review 7.  Fibroblast growth factor signaling controlling osteoblast differentiation.

Authors:  P J Marie
Journal:  Gene       Date:  2003-10-16       Impact factor: 3.688

8.  Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts.

Authors:  Jitesh Pratap; Mario Galindo; S Kaleem Zaidi; Diana Vradii; Bheem M Bhat; John A Robinson; Je-Yong Choi; Toshisha Komori; Janet L Stein; Jane B Lian; Gary S Stein; Andre J van Wijnen
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice.

Authors:  J D Coffin; R Z Florkiewicz; J Neumann; T Mort-Hopkins; G W Dorn; P Lightfoot; R German; P N Howles; A Kier; B A O'Toole
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

Review 10.  Molecular and cellular bases of syndromic craniosynostoses.

Authors:  Jacky Bonaventure; Vincent El Ghouzzi
Journal:  Expert Rev Mol Med       Date:  2003-01-29       Impact factor: 5.600

View more
  38 in total

Review 1.  Stereolithographic bone scaffold design parameters: osteogenic differentiation and signal expression.

Authors:  Kyobum Kim; Andrew Yeatts; David Dean; John P Fisher
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

3.  Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts.

Authors:  Estelle N Bianchi; Serge L Ferrari
Journal:  Bone       Date:  2009-06-25       Impact factor: 4.398

Review 4.  Role of syndecan-2 in osteoblast biology and pathology.

Authors:  Rafik Mansouri; Eric Haÿ; Pierre J Marie; Dominique Modrowski
Journal:  Bonekey Rep       Date:  2015-04-01

5.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

6.  Synergism between Wnt3a and heparin enhances osteogenesis via a phosphoinositide 3-kinase/Akt/RUNX2 pathway.

Authors:  Ling Ling; Christian Dombrowski; Kin Mun Foong; Larisa M Haupt; Gary S Stein; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

7.  Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Brian E Fuller; Michal A Zmijewski; Robert C Tuckey; Minh N Nguyen; Trevor Sweatman; Wei Li; Jordan Zjawiony; Duane Miller; Tai C Chen; Gerard Lozanski; Michael F Holick
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

8.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

Review 9.  Heparan sulfate biosynthesis: regulation and variability.

Authors:  Johan Kreuger; Lena Kjellén
Journal:  J Histochem Cytochem       Date:  2012-10-04       Impact factor: 2.479

Review 10.  MicroRNA functions in osteogenesis and dysfunctions in osteoporosis.

Authors:  Andre J van Wijnen; Jeroen van de Peppel; Johannes P van Leeuwen; Jane B Lian; Gary S Stein; Jennifer J Westendorf; Merry-Jo Oursler; Hee-Jeong Im; Hanna Taipaleenmäki; Eric Hesse; Scott Riester; Sanjeev Kakar
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.